Abstract
Background: This article is a summary of clinical research results from a study beginning approximately 30 years ago. We have focused on human leukocyte antigens (HLA) as one of several important genetic factors for the formulation of effective personalized therapy for cancer patients that can be applied in clinical settings. HLA were also studied on the basis of the original study hypothesis that pathological states and pharmacokinetics are similar among patients with similar genetic information.
Methods: HLA antigens were serologically tested using the National Institutes of Health standard microlymphocytotoxicity method for HLA-A, -B, -C, -DR and -DQ from Aug. 1977 to Aug. 2005 (n=1753) and also tested for the reproducibility and validation over the period from Sept. 2005 to Feb. 2010 (n=209). In this study, it was shown that individuals could be identified and grouped according to pair-matched parameters generated from serum HLA profiles at the protein level to represent the genetic information.
Results: In patients with similar HLA profiles, the effective and ineffective personalized therapies were also similar, leading to a good ability for successful prognosis. With existing cancer therapies, 60.9% of patients experienced a positive outcome. However, 10.2% of patients received ineffective personalized therapy. If effective personalized therapy is not given, oral administration of Polysaccharide Kureha and/or fluoropyrimidines regimen will be needed for at least 2 years.
Conclusion: Our hypothesis that effective and ineffective personalized therapies are similar in patients with similar genetic information, resulting in accurate therapeutic prognosis, has been established.
